Exagen Inc. (XGN) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $3.07. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is XGN = $13 (+323.5% upside).
Valuation: XGN trades at a trailing Price-to-Earnings (P/E) of -3.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.09.
Financials: revenue is $67M, +13.6%/yr average growth. Net income is $20M (loss), growing at +18.1%/yr. Net profit margin is -30% (negative). Gross margin is 58.3% (+11.4 pp trend).
Balance sheet: total debt is $5M against $17M equity (Debt-to-Equity (D/E) ratio 0.31, conservative). Current ratio is 3.45 (strong liquidity). Debt-to-assets is 9.3%. Total assets: $58M.
Analyst outlook: 10 / 10 analysts rate XGN as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 78/100 (Pass), Growth 80/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).
